{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:29:41Z","timestamp":1792855781808,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018934","name":"Universit\u00e4t Greifswald","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018934","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mini-tablets (MTs) have gained increasing importance as age-appropriate dosage forms, particularly for pediatric patients, due to their ease of swallowing and flexible dosing capabilities. Despite their growing use, regulatory guidance and standardized quality control (QC) methods specifically adapted to MTs, especially extended-release (ER) formulations, are still lacking. This study investigates the suitability of two miniaturized dissolution apparatuses for evaluating ER MTs: a Mini-Paddle system, which is a geometrically downscaled version of the compendial Paddle (USP 2) apparatus, and a small-volume Reciprocating-Holder (USP 7) apparatus. Two commercially available pediatric ER MT drug products containing melatonin and sodium valproate were tested individually and in deliberately manipulated batches to assess the methods\u2019 sensitivity and discriminatory power. The Mini-Paddle apparatus reliably quantified drug release from melatonin MTs but encountered limitations with low-dose sodium valproate MTs, requiring the pooling of multiple units, which masked individual variability. Conversely, the small-volume Reciprocating-Holder enabled sensitive, single-unit testing for both products, effectively detecting batch-to-batch differences despite very low drug loads. Neither apparatus currently holds official compendial status, emphasizing the urgent need for regulatory recognition and standardized methodologies. This study highlights the critical need for sensitive, miniaturized dissolution methods tailored to the unique challenges of MTs to ensure consistent quality, safety, and efficacy, particularly in vulnerable populations. Future work should focus on harmonizing and validating miniaturized dissolution systems to support QC and regulatory acceptance of MT formulations.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12249-025-03252-y","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:25:54Z","timestamp":1764195954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Small-Volume Dissolution Testing of Pediatric Mini-Tablets Using Miniaturized USP Apparatuses: Regulatory and Methodological Considerations"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8025-2186","authenticated-orcid":false,"given":"Stefanie","family":"Broocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2031-4875","authenticated-orcid":false,"given":"Melanie","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-5780","authenticated-orcid":false,"given":"Sandra","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"3252_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1517\/17425247.2015.1060218","volume":"12","author":"FL Lopez","year":"2015","unstructured":"Lopez FL, Ernest TB, Tuleu C, Gul MO. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin Drug Deliv. 2015;12:1727\u201340.","journal-title":"Expert Opin Drug Deliv"},{"key":"3252_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijpharm.2016.07.054","volume":"514","author":"SR Ranmal","year":"2016","unstructured":"Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: insights into end-user perceptions, preferences and practices from the Children\u2019s Acceptability of Oral Formulations (CALF) study. Int J Pharm. 2016;514:296\u2013307.","journal-title":"Int J Pharm"},{"key":"3252_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ijpharm.2017.07.017","volume":"536","author":"J Walsh","year":"2018","unstructured":"Walsh J, Ranmal SR, Ernest TB, Liu F. Patient acceptability, safety and access: a balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int J Pharm. 2018;536:547\u201362.","journal-title":"Int J Pharm"},{"key":"3252_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/pharmaceutics12010044","volume":"12","author":"E Menditto","year":"2020","unstructured":"Menditto E, Orlando V, De Rosa G, Minghetti P, Musazzi U, Cahir C, et al. Patient centric pharmaceutical drug product design\u2014the impact on medication adherence. Pharmaceutics. 2020;12:44.","journal-title":"Pharmaceutics"},{"key":"3252_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0378-5173(98)00206-3","volume":"173","author":"P Lennartz","year":"1998","unstructured":"Lennartz P, Mielck JB. Minitabletting: improving the compactability of paracetamol powder mixtures. Int J Pharm. 1998;173:75\u201385.","journal-title":"Int J Pharm"},{"key":"3252_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/archdischild-2015-308227","volume":"101","author":"DA van Riet-Nales","year":"2016","unstructured":"van Riet-Nales DA, Schobben AFAM, Vromans H, Egberts TCG, Rademaker CMA. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Arch Dis Child. 2016;101:662\u20139.","journal-title":"Arch Dis Child"},{"key":"3252_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.xphs.2024.02.016","volume":"113","author":"S Meruva","year":"2024","unstructured":"Meruva S, Singaraju AB, Vinjamuri BP, Ternik R, Stagner WC. Current state of minitablet product design: a review. J Pharm Sci. 2024;113:1123\u201354.","journal-title":"J Pharm Sci"},{"key":"3252_CR8","unstructured":"European Medicines Agency Committee for Medicinal Products for Human use (CHMP). Reflection paper on the pharmaceutical development of medicines for use in the older population. EMA\/CHMP\/QWP\/292439\/2017 [Internet]. 2020; Available from: https:\/\/www.ema.europa.eu\/en\/pharmaceutical-development-medicines-use-older-population-scientific-guideline. Accessed 7 Jul 2025."},{"key":"3252_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/ph15010108","volume":"15","author":"G Zuccari","year":"2022","unstructured":"Zuccari G, Alfei S, Marimpietri D, Iurilli V, Barabino P, Marchitto L. Mini-tablets: a valid strategy to combine efficacy and safety in pediatrics. Pharmaceuticals. 2022;15:108.","journal-title":"Pharmaceuticals"},{"key":"3252_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/17425247.2014.951633","volume":"12","author":"A Aleksovski","year":"2015","unstructured":"Aleksovski A, Dreu R, Ga\u0161perlin M, Planin\u0161ek O. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert Opin Drug Deliv. 2015;12:65\u201384.","journal-title":"Expert Opin Drug Deliv"},{"key":"3252_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2431-13-81","volume":"13","author":"RH Richey","year":"2013","unstructured":"Richey RH, Shah UU, Peak M, Craig JV, Ford JL, Barker CE, et al. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr. 2013;13:81.","journal-title":"BMC Pediatr"},{"key":"3252_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/pharmaceutics12040375","volume":"12","author":"J Brustugun","year":"2020","unstructured":"Brustugun J, Birkedal Aas E, Tho I, Bjerknes K. Comparing two methods of tablet manipulation to adjust the Warfarin dose in paediatric care. Pharmaceutics. 2020;12:375.","journal-title":"Pharmaceutics"},{"key":"3252_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejpb.2020.08.014","volume":"156","author":"L Freerks","year":"2020","unstructured":"Freerks L, Sommerfeldt J, L\u00f6per PC, Klein S. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - a promising starting point for future PUMA applications. Eur J Pharm Biopharm. 2020;156:11\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR14","unstructured":"United States Pharmacopeial Convention, United States Pharmacopeial Convention. United States Pharmacopeia and National Formulary: Dissolution <711> [Internet]. 2023. Available from: https:\/\/online.uspnf.com\/uspnf\/document\/2_GUID-AC788D41-90A2-4F36-A6E7-769954A9ED09_10101_en-US?source=Activity. Accessed 7 Jul 2025."},{"key":"3252_CR15","unstructured":"European Directorate for the Quality of Medicines & Healthcare, editor. European Pharmacopoeia 11.2: 5.17.1. Recommendations on dissolution testing [Internet]. 2023. Available from: https:\/\/pheur.edqm.eu\/app\/11-2\/content\/11-2\/51701E.htm. Accessed 7 Jul 2025."},{"key":"3252_CR16","unstructured":"European Directorate for the Quality of Medicines & Healthcare, editor. European Pharmacopoeia 11.2: 2.9.3. Dissolution test for solid dosage forms [Internet]. 2023. Available from: https:\/\/pheur.edqm.eu\/app\/11-2\/content\/default\/20903E.htm. Accessed 7 Jul 2025."},{"key":"3252_CR17","unstructured":"European Medicines Agency Committee for Medicinal Products for Human use (CHMP). ICH guideline Q8 (R2) on pharmaceutical development. EMA\/CHMP\/ICH\/167068\/2004 [Internet]. 2017; Available from: https:\/\/www.ema.europa.eu\/en\/ich-q8-r2-pharmaceutical-development-scientific-guideline. Accessed 7 Jul 2025."},{"key":"3252_CR18","unstructured":"European Medicines Agency Committee for Proprietary Medicinal Products (CPMP). ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substance. CPMP\/ICH\/367\/96 [Internet]. 2000; Available from: https:\/\/www.ema.europa.eu\/en\/ich-q6a-specifications-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical-substances-scientific-guideline. Accessed 7 Jul 2025."},{"key":"3252_CR19","first-page":"6","volume":"13","author":"S Klein","year":"2006","unstructured":"Klein S. The mini paddle apparatus\u2013a useful tool in the early developmental stage? Experiences with immediate-release dosage forms. Dissolution Technol. 2006;13:6\u201311.","journal-title":"Dissolution Technol"},{"key":"3252_CR20","unstructured":"United States Pharmacopeial Convention, United States Pharmacopeial Convention, Inc. United States Pharmacopeia and National Formulary: In vitro and in vivo evaluation of dosage forms <1088> [Internet]. 2023. Available from: https:\/\/online.uspnf.com\/uspnf\/document\/2_GUID-0818140F-BBE0-4124-96DB-4A37CBF25659_30101_en-US?source=Search%20Results&highlight=%22apparatus%207%22. Accessed 7 Jul 2025."},{"key":"3252_CR21","unstructured":"United States Pharmacopeial Convention, United States Pharmacopeial Convention. United States Pharmacopeia and National Formulary: Drug Release<724> [Internet]. 2018. Available from: https:\/\/online.uspnf.com\/uspnf\/document\/1_GUID-1BF488DB-86ED-4A33-AF13-71C2F1EDA2F2_5_en-US. Accessed 7 Jul 2025."},{"key":"3252_CR22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ejpb.2013.06.004","volume":"85","author":"A Externbrink","year":"2013","unstructured":"Externbrink A, Clark MR, Friend DR, Klein S. Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring. Eur J Pharm Biopharm. 2013;85:966\u201373.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2016.10.012","volume":"110","author":"A Externbrink","year":"2017","unstructured":"Externbrink A, Eggenreich K, Eder S, Mohr S, Nickisch K, Klein S. Development and evaluation of accelerated drug release testing methods for a matrix-type intravaginal ring. Eur J Pharm Biopharm. 2017;110:1\u201312.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1208\/s12249-008-9161-6","volume":"9","author":"S Klein","year":"2008","unstructured":"Klein S, Shah VP. A standardized mini paddle apparatus as an alternative to the standard paddle. AAPS PharmSciTech. 2008;9:1179\u201384.","journal-title":"AAPS PharmSciTech"},{"key":"3252_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1208\/s12249-016-0671-3","volume":"18","author":"F Karkossa","year":"2017","unstructured":"Karkossa F, Krueger A, Urbaniak J, Klein S. Simulating different dosing scenarios for a child-appropriate valproate ER formulation in a new pediatric two-stage dissolution model. AAPS PharmSciTech. 2017;18:309\u201316.","journal-title":"AAPS PharmSciTech"},{"key":"3252_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2025.114655","author":"V Lura","year":"2025","unstructured":"Lura V, Lura A, Breitkreutz J, Klingmann V. The revival of the mini-tablets: recent advancements, classifications and expectations for the future. Eur J Pharm Biopharm. 2025. https:\/\/doi.org\/10.1016\/j.ejpb.2025.114655.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR27","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1208\/s12249-012-9851-y","volume":"13","author":"S Klein","year":"2012","unstructured":"Klein S, Buchanan NL, Buchanan CM. Miniaturized transfer models to predict the precipitation of poorly soluble weak bases upon entry into the small intestine. AAPS PharmSciTech. 2012;13:1230\u20135.","journal-title":"AAPS PharmSciTech"},{"key":"3252_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ijpharm.2014.06.060","volume":"473","author":"R Berthelsen","year":"2014","unstructured":"Berthelsen R, Sj\u00f6gren E, Jacobsen J, Kristensen J, Holm R, Abrahamsson B, et al. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs\u2014a fenofibrate case example. Int J Pharm. 2014;473:356\u201365.","journal-title":"Int J Pharm"},{"key":"3252_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejpb.2017.02.009","volume":"115","author":"C Litou","year":"2017","unstructured":"Litou C, Vertzoni M, Xu W, Kesisoglou F, Reppas C. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: data in biorelevant media and in human aspirates. Eur J Pharm Biopharm. 2017;115:94\u2013101.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR30","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1021\/acs.molpharmaceut.6b01129","volume":"14","author":"D Georgaka","year":"2017","unstructured":"Georgaka D, Butler J, Kesisoglou F, Reppas C, Vertzoni M. Evaluation of dissolution in the lower intestine and its impact on the absorption process of high dose low solubility drugs. Mol Pharm. 2017;14:4181\u201391.","journal-title":"Mol Pharm"},{"key":"3252_CR31","doi-asserted-by":"publisher","first-page":"106034","DOI":"10.1016\/j.ejps.2021.106034","volume":"168","author":"PJ O\u2019Dwyer","year":"2022","unstructured":"O\u2019Dwyer PJ, Box KJ, Imanidis G, Vertzoni M, Reppas C. On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state. Eur J Pharm Sci. 2022;168:106034.","journal-title":"Eur J Pharm Sci"},{"key":"3252_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejpb.2018.10.022","volume":"133","author":"E Wollmer","year":"2018","unstructured":"Wollmer E, Neal G, Whitaker MJ, Margetson D, Klein S. Biorelevant in vitro assessment of dissolution and compatibility properties of a novel paediatric hydrocortisone drug product following exposure of the drug product to child-appropriate administration fluids. Eur J Pharm Biopharm. 2018;133:277\u201384.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11095-020-02912-x","volume":"37","author":"E Wollmer","year":"2020","unstructured":"Wollmer E, Karkossa F, Freerks L, Hetberg A-E, Neal G, Porter J, et al. A biopredictive in vitro approach for assessing compatibility of a novel pediatric hydrocortisone drug product within common pediatric dosing vehicles. Pharm Res. 2020;37:203.","journal-title":"Pharm Res"},{"key":"3252_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejpb.2023.10.011","volume":"193","author":"L Freerks","year":"2023","unstructured":"Freerks L, Arien T, Mackie C, Inghelbrecht S, Klein S. A toolbox for mimicking gastrointestinal conditions in children: design and evaluation of biorelevant dissolution media for mimicking paediatric gastric- and small intestinal conditions. Eur J Pharm Biopharm. 2023;193:144\u201357.","journal-title":"Eur J Pharm Biopharm"},{"key":"3252_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.xphs.2021.05.003","volume":"111","author":"L Freerks","year":"2022","unstructured":"Freerks L, Zielke C, Tarnow M-J, Arien T, Mackie C, Inghelbrecht S, et al. A toolbox for mimicking gastrointestinal conditions in children: simulated paediatric breakfast media (SPBM) for addressing the variability of gastric contents after typical paediatric breakfasts. J Pharm Sci. 2022;111:51\u201361.","journal-title":"J Pharm Sci"},{"key":"3252_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/pharmaceutics2040351","volume":"2","author":"E Scheubel","year":"2010","unstructured":"Scheubel E, Lindenberg M, Beyssac E, Cardot J-M. Small volume dissolution testing as a powerful method during pharmaceutical development. Pharmaceutics. 2010;2:351\u201363.","journal-title":"Pharmaceutics"},{"key":"3252_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijpharm.2016.06.036","volume":"510","author":"B Wang","year":"2016","unstructured":"Wang B, Armenante PM. Experimental and computational determination of the hydrodynamics of mini vessel dissolution testing systems. Int J Pharm. 2016;510:336\u201349.","journal-title":"Int J Pharm"},{"key":"3252_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijpharm.2015.09.002","volume":"495","author":"K Stamatopoulos","year":"2015","unstructured":"Stamatopoulos K, Batchelor HK, Alberini F, Ramsay J, Simmons MJH. Understanding the impact of media viscosity on dissolution of a highly water soluble drug within a USP 2 mini vessel dissolution apparatus using an optical planar induced fluorescence (PLIF) method. Int J Pharm. 2015;495:362\u201373.","journal-title":"Int J Pharm"},{"key":"3252_CR39","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/bcp.13956","volume":"85","author":"AC Van Der Vossen","year":"2019","unstructured":"Van Der Vossen AC, Hanff LM, Vulto AG, Fotaki N. Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam. Br J Clin Pharmacol. 2019;85:1728\u201339.","journal-title":"Br J Clin Pharmacol"},{"key":"3252_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12249-020-01825-7","volume":"21","author":"J Martir","year":"2020","unstructured":"Martir J, Flanagan T, Mann J, Fotaki N. In vivo predictive dissolution testing of Montelukast sodium formulations administered with drinks and soft foods to infants. AAPS PharmSciTech. 2020;21:282.","journal-title":"AAPS PharmSciTech"},{"key":"3252_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1208\/s12248-021-00661-2","volume":"24","author":"M Guimar\u00e3es","year":"2022","unstructured":"Guimar\u00e3es M, Somville P, Vertzoni M, Fotaki N. Performance evaluation of Montelukast pediatric formulations: Part I\u2014age-related in vitro conditions. AAPS J. 2022;24:26.","journal-title":"AAPS J"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03252-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03252-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03252-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:04:47Z","timestamp":1770314687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03252-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3252"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03252-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The commercially available extended-release drug products tested in this study were obtained through regular pharmaceutical wholesalers. The manufacturers of the investigated products were not informed about the study and had no influence on the conduct of the experiments or the interpretation and discussion of the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"46"}}